Bon Natural Life (BON) Competitors $1.43 -0.03 (-1.92%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$1.46 +0.03 (+2.30%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock BON vs. SRNE, REVB, BIOR, VIRX, ATXI, SYRS, NCNA, BPTSY, VRPX, and KRBPShould you be buying Bon Natural Life stock or one of its competitors? The main competitors of Bon Natural Life include Sorrento Therapeutics (SRNE), Revelation Biosciences (REVB), Biora Therapeutics (BIOR), Viracta Therapeutics (VIRX), Avenue Therapeutics (ATXI), Syros Pharmaceuticals (SYRS), NuCana (NCNA), Biophytis (BPTSY), Virpax Pharmaceuticals (VRPX), and Kiromic BioPharma (KRBP). These companies are all part of the "pharmaceutical products" industry. Bon Natural Life vs. Its Competitors Sorrento Therapeutics Revelation Biosciences Biora Therapeutics Viracta Therapeutics Avenue Therapeutics Syros Pharmaceuticals NuCana Biophytis Virpax Pharmaceuticals Kiromic BioPharma Sorrento Therapeutics (NASDAQ:SRNE) and Bon Natural Life (NYSE:BON) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk. Which has stronger valuation and earnings, SRNE or BON? Bon Natural Life has lower revenue, but higher earnings than Sorrento Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSorrento Therapeutics$60.32M0.01-$572.84MN/AN/ABon Natural Life$23.84M0.01$400KN/AN/A Does the media prefer SRNE or BON? In the previous week, Bon Natural Life had 2 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 4 mentions for Bon Natural Life and 2 mentions for Sorrento Therapeutics. Bon Natural Life's average media sentiment score of 0.68 beat Sorrento Therapeutics' score of 0.00 indicating that Bon Natural Life is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sorrento Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bon Natural Life 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, SRNE or BON? Sorrento Therapeutics has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Bon Natural Life has a beta of -0.49, suggesting that its share price is 149% less volatile than the S&P 500. Is SRNE or BON more profitable? Company Net Margins Return on Equity Return on Assets Sorrento TherapeuticsN/A N/A N/A Bon Natural Life N/A N/A N/A Do institutionals and insiders have more ownership in SRNE or BON? 0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by insiders. Comparatively, 26.5% of Bon Natural Life shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryBon Natural Life beats Sorrento Therapeutics on 5 of the 8 factors compared between the two stocks. Get Bon Natural Life News Delivered to You Automatically Sign up to receive the latest news and ratings for BON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BON vs. The Competition Export to ExcelMetricBon Natural LifeMedicinals & botanicals IndustryDiscretionary SectorNYSE ExchangeMarket Cap$239K$3.79B$8.31B$20.72BDividend YieldN/AN/A3.17%3.72%P/E RatioN/A8.4121.0628.09Price / Sales0.0129.833.3438.30Price / Cash0.785.6217.5022.53Price / Book0.041.304.624.58Net Income$400K$20.24M$213.40M$986.06M7 Day Performance13.65%4.68%3.45%2.79%1 Month Performance-20.00%-5.80%11.01%5.46%1 Year Performance-97.62%-25.64%10.66%15.06% Bon Natural Life Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BONBon Natural LifeN/A$1.43-1.9%N/A-97.6%$239K$23.84M0.00100Gap DownSRNESorrento Therapeutics0.7136 of 5 stars$0.00-36.4%N/A-81.7%$772K$60.32M0.00800News CoverageGap DownREVBRevelation Biosciences0.4772 of 5 stars$0.75-1.2%N/A-97.3%$730KN/A-0.0110Gap DownBIORBiora TherapeuticsN/A$0.15+6.5%$23.00+15,664.2%-97.7%$660K$892K-0.01120Gap UpVIRXViracta Therapeutics2.1605 of 5 stars$0.02-6.7%$1.75+10,442.2%-96.6%$660KN/A-0.0220Gap DownATXIAvenue Therapeutics2.587 of 5 stars$0.20-16.5%N/A-90.0%$639KN/A0.014Trending NewsGap DownSYRSSyros Pharmaceuticals4.3589 of 5 stars$0.02-25.8%$3.33+14,915.0%-99.5%$596K$386K-0.01120Gap DownNCNANuCana2.5391 of 5 stars$0.06-33.2%$25.00+43,454.0%-98.0%$520KN/A-0.0130Gap DownHigh Trading VolumeBPTSYBiophytisN/A$1.38flatN/A-79.7%$484KN/A0.0030VRPXVirpax Pharmaceuticals1.3788 of 5 stars$0.32+0.3%$75.00+23,634.2%-97.1%$392KN/A0.007KRBPKiromic BioPharmaN/AN/AN/AN/A$330KN/A-0.0660Gap DownHigh Trading Volume Related Companies and Tools Related Companies Sorrento Therapeutics Competitors Revelation Biosciences Competitors Biora Therapeutics Competitors Viracta Therapeutics Competitors Avenue Therapeutics Competitors Syros Pharmaceuticals Competitors NuCana Competitors Biophytis Competitors Virpax Pharmaceuticals Competitors Kiromic BioPharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BON) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bon Natural Life Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bon Natural Life With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
